Skip to main content

Positron Emission Tomography with PSMA as biomarker (PSMA PET)

Prostate-Specific Membrane Antigen (PSMA)

Let's explore this subject together
 
Prof Carlos Artigas,
Nuclear doctor

PSMA PET is an innovative imaging technology used to detect and localise with great precision the presence of prostate cancer cells in the body. The patient is injected with a radioactive tracer that targets specifically the PSMA, a protein that is highly expressed on the membrane of prostatic cancer cells.

Revealing the invisible

The use of PSMA PET marks significant progress in prostate cancer treatment, in particular thanks to its ability to provide a precise extension assessment of the disease. Traditionally, examinations such as the scan or bone scintigraphy were limited when it came to detecting small metastases or localised recurrence, especially in the lymph nodes or bones. These examinations are often not very sensitive and this can result in the extent of the cancer being under-estimated, thereby affecting treatment decisions. 

At the Willy Grégoir Prostate Cancer Centre we were the first in Belgium and among the first worldwide to implement this revolutionary imaging and we have been actively involved in its dissemination